Harvard Apparatus (HART) Reports Q3 Loss of $0.19/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St falls as bond yields test multi-decade highs
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
HART Reports Q3 Financial Results and Provides Business Update
November 12, 2015 4:06 PM ESTHOLLISTON, Mass., Nov. 12, 2015 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today reported third quarter financial results and provided a business update. Separately this morning, HART reported significant results from research involving its second-generation (Gen2) bioengineered trachea, bronchus and esophagus implants in large animals (Click here for... More
